Financial Data and Key Metrics Changes - The company reported a 56% growth in revenue to AUD 804 million, marking its third consecutive year of double-digit revenue growth [18][20] - EBITDA improved by 25% to AUD 216 million, driven by strong demand for Illuccix and the launch of Gozellix [20][23] - The gross margin remained stable at 53%, with 94% of gross margin generated from the precision medicine business [21][22] Business Line Data and Key Metrics Changes - Revenue from the precision medicine business increased by 22% year-over-year, contributing an additional AUD 113 million [20][23] - The precision medicine business demonstrated a 28% increase in operating profit and a 25% increase in EBITDA [23] - The company invested AUD 157 million into product development, focusing on its late-stage pipeline [22] Market Data and Key Metrics Changes - The precision medicine portfolio generated AUD 622 million in revenue, up 22% year-over-year, with sequential growth every quarter [31] - Illuccix is now available in 17 countries with reimbursement secured, and marketing authorizations in over 24 markets [35] - The company anticipates a 25% growth in its precision medicine business for 2026, driven by the full year of RLS revenue [28] Company Strategy and Development Direction - The company aims to transition to a high-value therapeutic business, with planned R&D investment in the range of AUD 200 million to AUD 240 million for 2026 [26] - The focus will remain on reinvesting revenues back into the business rather than optimizing near-term earnings per share [26][72] - The company is committed to building long-term value through disciplined capital allocation and strategic investments in R&D and commercial performance [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of roughly 20%+ revenue growth in 2026, with guidance set at AUD 950 million to AUD 970 million [28][30] - The company is focused on executing its strategic plan to grow the precision medicine business by expanding product offerings and geographic reach [35] - Management acknowledged the challenges faced with regulatory approvals but emphasized the importance of learning from these experiences to enhance future submissions [15][72] Other Important Information - The company has over 30 sponsored and collaborative studies running, with four major trials highlighted as priorities for the year [49] - The ProstACT Global study is currently recruiting for part two, with results expected to be released soon [50] - The company has made extensive changes to its management team and regulatory affairs capabilities to improve future product submissions [15] Q&A Session Summary Question: When might data for 591 be available? - Management indicated that the company is not waiting on the FDA and will disclose data as soon as it is available [56][58] Question: Insights on the two-product strategy for Illuccix and Gozellix? - The two-product strategy allows the company to manage economic needs and preferences of different customer types, adapting to changes in reimbursement environments [61][62] Question: Clarification on reinvesting earnings for future years? - Management confirmed that the majority of earnings will be reinvested back into the company for growth, particularly in R&D and commercial development [72] Question: Growth contribution from markets outside the US? - Currently, 95% of revenue is US-based, but the company expects this mix to change as it expands into other markets [78] Question: Will R&D spending be adjusted based on commercial performance? - Management stated that R&D investment is discretionary and can be adjusted based on commercial performance, focusing on priority studies [75][76]

Telix Pharmaceuticals (NasdaqGS:TLX) H2 2025 Earnings call February 19, 2026 05:30 PM ET Speaker13Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Kyahn Williamson, SVP of Investor Relations and Corporate Communications. Please go ahead.Speaker9Thank you, and thank you to everybody for joining us on this call this morning, this evening, wherever you are in the world. We launched our annual report and full year results on the ASX ...